Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

This study has been completed.
Information provided by (Responsible Party):
University of New Mexico Identifier:
First received: February 28, 2006
Last updated: May 10, 2016
Last verified: May 2016
The Tissue Repository will search for cases, pull slides, Paraffin-embedded tissue (PET) blocks.

Condition Intervention
Cervical Cancer
Genetic: Tissue Repository

Study Type: Interventional
Official Title: Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

Resource links provided by NLM:

Further study details as provided by University of New Mexico:

Enrollment: 300
Study Start Date: December 2005
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Detailed Description:

This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future.

This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Samples from patients diagnosed with HG-SIL (n=300) and CC (n=300) with a follow-up of at least 24 months, existing at the Department of Pathology will be retrieved by the Tissue Repository, de-identified them and provided with code numbers that will not be linked to patient's data.

Exclusion Criteria:

  • None Specified.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00298064

United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Principal Investigator: Claire Verschraegen, MD University of New Mexico
  More Information

Responsible Party: University of New Mexico Identifier: NCT00298064     History of Changes
Other Study ID Numbers: INST 0548C
Study First Received: February 28, 2006
Last Updated: May 10, 2016

Keywords provided by University of New Mexico:
Cervical cancer
epidermal growth factor

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female processed this record on April 28, 2017